{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=20", "query": { "condition": "Phase 2 Study", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 17251, "total_pages": 1726, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T18:51:57.216Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02888743", "title": "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2017-08-14", "completion_date": "2027-01-02", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02888743" }, { "nct_id": "NCT02553135", "title": "Choroideremia Gene Therapy Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Choroideremia" ], "interventions": [ { "name": "Injection of AAV2-REP1 (10e11 vg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Byron Lam", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2015-09", "completion_date": "2018-02", "has_results": true, "last_update_posted_date": "2019-07-29", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02553135" }, { "nct_id": "NCT04436276", "title": "A Study of Ad26.COV2.S in Adults (COVID-19)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Covid-19 Prevention" ], "interventions": [ { "name": "Ad26.COV2.S", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1085, "start_date": "2020-07-15", "completion_date": "2023-02-21", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 7, "location_summary": "San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04436276" }, { "nct_id": "NCT04891289", "title": "Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Floxuridine (FUDR)", "type": "DRUG" }, { "name": "Implanted Medical Device", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2021-05-07", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 10, "location_summary": "Bethesda, Maryland • St Louis, Missouri • Basking Ridge, New Jersey + 7 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04891289" }, { "nct_id": "NCT00196989", "title": "Study In People With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "GW677954", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 448, "start_date": "2005-09", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00196989" }, { "nct_id": "NCT04589650", "title": "Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PIK3CA-related Overgrowth Spectrum (PROS)" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "100 Years", "sex": "ALL", "summary": "0 Days to 100 Years" }, "enrollment_count": 236, "start_date": "2021-04-19", "completion_date": "2031-01-09", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 11, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589650" }, { "nct_id": "NCT02129660", "title": "Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperhidrosis" ], "interventions": [ { "name": "Dose 1 of glycopyrrolate, 2.0% QD", "type": "DRUG" }, { "name": "Dose 2 of glycopyrrolate, 3.0% QD", "type": "DRUG" }, { "name": "Dose 1 of glycopyrronium, 2.5% QD", "type": "DRUG" }, { "name": "Dose 2 of glycopyrronium, 3.75% QD", "type": "DRUG" }, { "name": "Vehicle", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Journey Medical Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 105, "start_date": "2014-04", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 14, "location_summary": "Encinitas, California • Fremont, California • Tampa, Florida + 10 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Carmel", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02129660" }, { "nct_id": "NCT00389155", "title": "First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Bladder Cancer", "Transitional Cell Carcinoma", "Metastasis" ], "interventions": [ { "name": "Vinflunine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2007-01", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00389155" }, { "nct_id": "NCT02777385", "title": "Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "IMRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2016-05-31", "completion_date": "2023-05-04", "has_results": true, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02777385" }, { "nct_id": "NCT02188368", "title": "Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "POM", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" }, { "name": "CFZ", "type": "DRUG" }, { "name": "BTZ", "type": "DRUG" }, { "name": "CLA", "type": "DRUG" }, { "name": "CY", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-07-07", "completion_date": "2020-10-23", "has_results": false, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-10-21T18:51:57.216Z", "location_count": 12, "location_summary": "Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188368" } ] }